Leanbio opens new GMP facilities to expand its production capacities in Barcelona, Spain.
The site is planned with an area of 4,000 square metres. The new facility will house developmental and quality control laboratories, pilot plants, commercial production lines, and various services including cell banking, upstream processing, downstream processing, and GMP batch release.
The facility will include three GMP lines dedicated to mammalian cells, microbial cultures, plasmid DNA, and mRNA for advanced therapies.
These lines will have a supply capacity, starting at 2000 litres initially, and will adhere to regulatory standards set by the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA).
The facility comprises three distinct segregated zones for the production of proteins and nucleic acids:
Construction is currently underway, and the facility is scheduled to become operational in the first half of 2025.
Name Leanbio Pro
Type New Construction